Clinical Trials Browser

LCL161 × Plasma cell × Clear all

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase 1 Completed

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01955434 2019-09-10

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

25 enrolled 6 charts

Multiple Myeloma